Beta Synuclein Protein

€117,700.00
(No reviews yet) Write a Review
SKU:
SPR-457E
Availability:
Next week
Shipping:
Calculated at Checkout
Size:
5x100 µg
Species:
Human
Specificity:
14.28 kDa
Conjugate:
No tag
Storage Temperature:
-80ºC
Purity:
>95%
Adding to cart… The item has been added

Beta Synuclein Protein is available at Gentaur for Next week delivery.

Description:  Active Human Recombinant Beta Synuclein Protein Preformed Fibrils (Type 1)

Alternative Name(s):  14 kDa brain-specific protein aggregates, Beta-synuclein Protein Aggregates, Phosphoneuroprotein 14 Protein Aggregates, PNP14 Protein Aggregates, Sncb Protein Aggregates, Synuclein beta Protein Aggregates, SYUB_HUMAN Protein Aggregates

Research Area(s):  Neuroscience | Neurodegeneration | Alzheimer's Disease | Tangles & Tau | Neuroscience | Neurodegeneration | Parkinson's Disease | Synuclein

Nature:  Recombinant

Accession Number: NP_001001502.1

Gene ID:  6620

Swiss-Prot:  Q16143 

Applications Species:  WB | SDS-PAGE | In vivo assay | In vitro assay 

Biological Activity: 

Expression System: E. coli

Protein Length:  Full length

Amino Acid Sequence:

Purification:  Ion-exchange Purified

Storage Buffer:  PBS pH 7.4

Concentration:  Lot/batch specific. See included datasheet.

Shipping Temperature: Dry Ice. Shipping note: Product will be shipped separately from other products purchased in the same order.

Other relevant information: For best results, sonicate immediately prior to use. Refer to the Neurodegenerative Protein Handling Instructions on our website, or on the product datasheet for further information..

Certificate of Analysis: Certified >95% pure using SDS-PAGE analysis. 

Cellular Localization:  Cytoplasm

Scientific Background:  Alzheimer’s Disease (AD) is the most common neurodegenerative disease, affecting 10% of seniors over the age of 65 (1). It was named after Alois Alzheimer, a German scientist who discovered tangled bundles of fibrils where neurons had once been in the brain of a deceased patient in 1907 (2). Beta synuclein is abundant in neurofibrillary lesions of patients with Alzheimer's Disease. Beta synuclein is suggested to be an inhibitor of alpha synuclein aggregation- protecting the central nervous system from the neurotoxin effects of alpha synuclein (3).

References: 1. www.alz.org/alzheimers-dementia/facts-figures 2. Alzheimer, A. Über eine eigenartige Erkrankung der Hirnrinde. Allg. Z. Psychiatr. Psych.-Gerichtl. Med. 64, 146–148 (1907). 3. Taschenberger G., et al. (2013) Ann Neurol. 74(1): 109-118.

Field of Use:  Not for use in humans. Not for use in diagnostics or therapeutics. For research use only.

PubMed ID: 

Published Application: 

Published Species Reactivity: 

"